Toronto Dominion Bank’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.06M Buy
46,712
+38,245
+452% +$7.09M 0.01% 693
2025
Q4
$1.69M Sell
8,467
-12,675
-60% -$2.3M ﹤0.01% 1160
2025
Q3
$3.31M Buy
21,142
+10,220
+94% +$1.62M 0.01% 908
2025
Q2
$1.66M Buy
10,922
+753
+7% +$100K ﹤0.01% 1017
2025
Q1
$1.53M Sell
10,169
-7,167
-41% -$1.2M ﹤0.01% 1002
2024
Q4
$3.2M Sell
17,336
-8,281
-32% -$1.6M 0.01% 813
2024
Q3
$5.05M Buy
25,617
+397
+2% +$82.5K 0.01% 612
2024
Q2
$5.21M Sell
25,220
-3,812
-13% -$864K 0.01% 626
2024
Q1
$7.87M Buy
29,032
+606
+2% +$145K 0.01% 548
2023
Q4
$6.72M Buy
28,426
+7,973
+39% +$1.57M 0.01% 652
2023
Q3
$4.01M Sell
20,453
-2,416
-11% -$496K 0.01% 738
2023
Q2
$4.8M Sell
22,869
-2,775
-11% -$552K 0.01% 708
2023
Q1
$5.17M Buy
25,644
+29
+0.1% +$6.57K 0.01% 671
2022
Q4
$5.58M Buy
25,615
+3,655
+17% +$798K 0.01% 662
2022
Q3
$4.32M Sell
21,960
-4,078
-16% -$880K 0.01% 707
2022
Q2
$5.57M Sell
26,038
-3,915
-13% -$957K 0.01% 550
2022
Q1
$8.51M Buy
29,953
+251
+0.8% +$77.4K 0.01% 497
2021
Q4
$11.2M Buy
29,702
+2,287
+8% +$889K 0.02% 475
2021
Q3
$11.3M Buy
27,415
+5,386
+24% +$2.24M 0.02% 421
2021
Q2
$8.15M Buy
+22,029
New +$7.36M 0.01% 507
2020
Q4
Sell
-4
Closed -$1K 1362
2020
Q3
$1K Hold
4
﹤0.01% 1176
2020
Q2
$1K Buy
+4
New +$638 ﹤0.01% 1190
2019
Q4
Sell
-26
Closed -$3K 1380
2019
Q3
$3K Sell
26
-26
-50% -$3.49K ﹤0.01% 1354
2019
Q2
$4K Buy
+52
New +$7.05K ﹤0.01% 1300
2013
Q3
Sell
-1,200
Closed -$49K 778
2013
Q2
$49K Buy
+1,200
New +$51.4K ﹤0.01% 649

Other funds holding CRL

Toronto Dominion Bank's CRL Position: Q1 2026 in Review

Toronto Dominion Bank increased its Charles River Laboratories (CRL) stake by 452% in Q1 2026, buying an estimated $7.09M and bringing the position to 46,712 shares worth $8.06M. The position accounts for 0.01% of the portfolio, ranked #693.

Toronto Dominion Bank first reported a position in CRL in Q2 2013 and has held it in 25 quarters since. The position peaked at $11.3M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Toronto Dominion Bank held 46,712 shares of Charles River Laboratories worth $8.06M as of Q1 2026.
  • Toronto Dominion Bank bought 38,245 Charles River Laboratories shares in Q1 2026, an estimated $7.09M.
  • Charles River Laboratories made up 0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #693 holding.
  • Toronto Dominion Bank first reported a position in Charles River Laboratories in Q2 2013 and has held it in 25 quarters since.
  • Toronto Dominion Bank's Charles River Laboratories position peaked at $11.3M in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.